Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Algenpantucel-L with Chemoradiation for Borderline Resectable Pancreatic Cancer
NCT02405585Phase 2Terminated
- Sponsor
- Lumos Pharma, Inc.
- Start
- Apr 2015
- Primary completion
- Jun 2016
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of algenpantucel-L in pancreatic cancer (PC), sponsored by Lumos Pharma, Inc.. Started Apr 2015; status: terminated.
02
Drugs
algenpantucel-L
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02405585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02405585.